## Maria Francesca Alvisi

## List of Publications by Year

 in descending orderSource: https:|/exaly.com/author-pdf/7347293/publications.pdf
Version: 2024-02-01


High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind,
multicentre, phase II, dose-finding, proof-of-concept clinical trial. International Journal of
Antimicrobial Agents, 2022,59, 106516.

How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study. Supportive Care in Cancer, 2021, 29, 645-651.
2.5

32
32

$2.2 \quad 8$

Predicting the Role of DNA Polymerase $\hat{1}^{2}$ Alone or with KRAS Mutations in Advanced NSCLC Patients
Receiving Platinum-Based Chemotherapy. Journal of Clinical Medicine, 2020, 9, 2438.

Impact of ERCC1, XPF and DNA Polymerase $\hat{1}^{2}$ Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. Cancers, 2020, 12, 2398.
3.7

9

Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in
Patients With Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2020, 14, 1190-1201.
1.3

18

Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?. Frontiers in Psychology, 2020, 11, 576459.

Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance. Tumori, 2018, 104, 172-178.
1.1

5

Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?.
Tumori, 2017, 103, 464-474.
â€œWhat ifâ€|â€! Decisional Regret in Patients who Discontinued Active Surveillance. Tumori, 2016, 102,
562-568.
1.1

6

Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. European Urology, 2013, 64, 30-36.

